 | • レポートコード：QFJ1-4118 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、デビック症候群（視神経脊髄炎）治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（エクリズマブ、メチルプレドニゾロン、アザチオプリン、ミコフェノール酸モフェチル、リツキシマブ）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・デビック症候群（視神経脊髄炎）治療の市場動向 ・企業の競争状況、市場シェア ・デビック症候群（視神経脊髄炎）治療の種類別市場規模と予測2016-2027（エクリズマブ、メチルプレドニゾロン、アザチオプリン、ミコフェノール酸モフェチル、リツキシマブ） ・デビック症候群（視神経脊髄炎）治療の用途別市場規模と予測2016-2027（病院、診療所、その他） ・デビック症候群（視神経脊髄炎）治療の北米市場規模2016-2027（アメリカ、カナダ） ・デビック症候群（視神経脊髄炎）治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・デビック症候群（視神経脊髄炎）治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・デビック症候群（視神経脊髄炎）治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・デビック症候群（視神経脊髄炎）治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Alexion Pharmaceuticals, Inc.、Teva Pharmaceuticals、Fresenius Kabi AG、Pharmacia & Upjohn (a subsidary of Pfizer)、Lupin Ltd.、Sagent Pharmaceuticals, Inc.、Zydus Pharmaceuticals, Inc.、Sandoz Inc. (Novartis)、Alkem Laboratories Ltd.、Mylan Pharmaceuticals, Inc.、Hoffmann-La Roche/ Chugai Pharmaceutical、MedImmune LLC、RemeGen, Ltd.） ・結論 |
Devic’s syndrome is also known as neuromyelitis optica which is a central nervous system disorder that specifically affects eye nerves and spinal cord.
Market Analysis and Insights: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
The global Devic’s Syndrome (Neuromyelitis Optica) Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market.
Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Scope and Market Size
Devic’s Syndrome (Neuromyelitis Optica) Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Eculizumab
Methylprednisolone
Azathioprine
Mycophenolate Mofetil
Rituximab
Segment by Application
Hospitals
Clinic
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Alexion Pharmaceuticals, Inc.
Teva Pharmaceuticals
Fresenius Kabi AG
Pharmacia & Upjohn (a subsidary of Pfizer)
Lupin Ltd.
Sagent Pharmaceuticals, Inc.
Zydus Pharmaceuticals, Inc.
Sandoz Inc. (Novartis)
Alkem Laboratories Ltd.
Mylan Pharmaceuticals, Inc.
Hoffmann-La Roche/ Chugai Pharmaceutical
MedImmune LLC
RemeGen, Ltd.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Eculizumab
1.2.3 Methylprednisolone
1.2.4 Azathioprine
1.2.5 Mycophenolate Mofetil
1.2.6 Rituximab
1.3 Market by Application
1.3.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Perspective (2016-2027)
2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Growth Trends by Regions
2.2.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Industry Dynamic
2.3.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Trends
2.3.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
2.3.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges
2.3.4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue
3.1.1 Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Revenue (2016-2021)
3.1.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue
3.4 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio
3.4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2020
3.5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Key Players Head office and Area Served
3.6 Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
3.7 Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Type
4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Type (2016-2021)
4.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2022-2027)
5 Devic’s Syndrome (Neuromyelitis Optica) Treatment Breakdown Data by Application
5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Historic Market Size by Application (2016-2021)
5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
6.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
6.2.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
6.2.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
6.2.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
6.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
6.3.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
6.3.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
6.3.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
6.4 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
6.4.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021)
6.4.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
7.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
7.2.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
7.2.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
7.2.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
7.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
7.3.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
7.3.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
7.3.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
7.4 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
7.4.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021)
7.4.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
8.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
8.2.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
8.3.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region
8.4.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
9.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
9.2.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
9.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
9.3.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
9.4 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
9.4.1 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (2016-2027)
10.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type
10.2.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application
10.3.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
10.4.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Alexion Pharmaceuticals, Inc.
11.1.1 Alexion Pharmaceuticals, Inc. Company Details
11.1.2 Alexion Pharmaceuticals, Inc. Business Overview
11.1.3 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.1.4 Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.1.5 Alexion Pharmaceuticals, Inc. Recent Development
11.2 Teva Pharmaceuticals
11.2.1 Teva Pharmaceuticals Company Details
11.2.2 Teva Pharmaceuticals Business Overview
11.2.3 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.2.4 Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.2.5 Teva Pharmaceuticals Recent Development
11.3 Fresenius Kabi AG
11.3.1 Fresenius Kabi AG Company Details
11.3.2 Fresenius Kabi AG Business Overview
11.3.3 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.3.4 Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.3.5 Fresenius Kabi AG Recent Development
11.4 Pharmacia & Upjohn (a subsidary of Pfizer)
11.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
11.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
11.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development
11.5 Lupin Ltd.
11.5.1 Lupin Ltd. Company Details
11.5.2 Lupin Ltd. Business Overview
11.5.3 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.5.4 Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.5.5 Lupin Ltd. Recent Development
11.6 Sagent Pharmaceuticals, Inc.
11.6.1 Sagent Pharmaceuticals, Inc. Company Details
11.6.2 Sagent Pharmaceuticals, Inc. Business Overview
11.6.3 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.6.4 Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.6.5 Sagent Pharmaceuticals, Inc. Recent Development
11.7 Zydus Pharmaceuticals, Inc.
11.7.1 Zydus Pharmaceuticals, Inc. Company Details
11.7.2 Zydus Pharmaceuticals, Inc. Business Overview
11.7.3 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.7.4 Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.7.5 Zydus Pharmaceuticals, Inc. Recent Development
11.8 Sandoz Inc. (Novartis)
11.8.1 Sandoz Inc. (Novartis) Company Details
11.8.2 Sandoz Inc. (Novartis) Business Overview
11.8.3 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.8.4 Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.8.5 Sandoz Inc. (Novartis) Recent Development
11.9 Alkem Laboratories Ltd.
11.9.1 Alkem Laboratories Ltd. Company Details
11.9.2 Alkem Laboratories Ltd. Business Overview
11.9.3 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.9.4 Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.9.5 Alkem Laboratories Ltd. Recent Development
11.10 Mylan Pharmaceuticals, Inc.
11.10.1 Mylan Pharmaceuticals, Inc. Company Details
11.10.2 Mylan Pharmaceuticals, Inc. Business Overview
11.10.3 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.10.4 Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.10.5 Mylan Pharmaceuticals, Inc. Recent Development
11.11 Hoffmann-La Roche/ Chugai Pharmaceutical
11.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
11.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
11.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
11.12 MedImmune LLC
11.12.1 MedImmune LLC Company Details
11.12.2 MedImmune LLC Business Overview
11.12.3 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.12.4 MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.12.5 MedImmune LLC Recent Development
11.13 RemeGen, Ltd.
11.13.1 RemeGen, Ltd. Company Details
11.13.2 RemeGen, Ltd. Business Overview
11.13.3 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Introduction
11.13.4 RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
11.13.5 RemeGen, Ltd. Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Eculizumab
Table 3. Key Players of Methylprednisolone
Table 4. Key Players of Azathioprine
Table 5. Key Players of Mycophenolate Mofetil
Table 6. Key Players of Rituximab
Table 7. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions (2016-2021)
Table 11. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions (2022-2027)
Table 13. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Trends
Table 14. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
Table 15. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Challenges
Table 16. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints
Table 17. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Players (2016-2021)
Table 19. Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment as of 2020)
Table 20. Ranking of Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Product Solution and Service
Table 24. Date of Enter into Devic’s Syndrome (Neuromyelitis Optica) Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Alexion Pharmaceuticals, Inc. Company Details
Table 65. Alexion Pharmaceuticals, Inc. Business Overview
Table 66. Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 67. Alexion Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 68. Alexion Pharmaceuticals, Inc. Recent Development
Table 69. Teva Pharmaceuticals Company Details
Table 70. Teva Pharmaceuticals Business Overview
Table 71. Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 72. Teva Pharmaceuticals Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 73. Teva Pharmaceuticals Recent Development
Table 74. Fresenius Kabi AG Company Details
Table 75. Fresenius Kabi AG Business Overview
Table 76. Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 77. Fresenius Kabi AG Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 78. Fresenius Kabi AG Recent Development
Table 79. Pharmacia & Upjohn (a subsidary of Pfizer) Company Details
Table 80. Pharmacia & Upjohn (a subsidary of Pfizer) Business Overview
Table 81. Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 82. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 83. Pharmacia & Upjohn (a subsidary of Pfizer) Recent Development
Table 84. Lupin Ltd. Company Details
Table 85. Lupin Ltd. Business Overview
Table 86. Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 87. Lupin Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 88. Lupin Ltd. Recent Development
Table 89. Sagent Pharmaceuticals, Inc. Company Details
Table 90. Sagent Pharmaceuticals, Inc. Business Overview
Table 91. Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 92. Sagent Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 93. Sagent Pharmaceuticals, Inc. Recent Development
Table 94. Zydus Pharmaceuticals, Inc. Company Details
Table 95. Zydus Pharmaceuticals, Inc. Business Overview
Table 96. Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 97. Zydus Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 98. Zydus Pharmaceuticals, Inc. Recent Development
Table 99. Sandoz Inc. (Novartis) Company Details
Table 100. Sandoz Inc. (Novartis) Business Overview
Table 101. Sandoz Inc. (Novartis) Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 102. Sandoz Inc. (Novartis) Recent Development
Table 103. Alkem Laboratories Ltd. Company Details
Table 104. Alkem Laboratories Ltd. Business Overview
Table 105. Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 106. Alkem Laboratories Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 107. Alkem Laboratories Ltd. Recent Development
Table 108. Mylan Pharmaceuticals, Inc. Company Details
Table 109. Mylan Pharmaceuticals, Inc. Business Overview
Table 110. Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 111. Mylan Pharmaceuticals, Inc. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 112. Mylan Pharmaceuticals, Inc. Recent Development
Table 113. Hoffmann-La Roche/ Chugai Pharmaceutical Company Details
Table 114. Hoffmann-La Roche/ Chugai Pharmaceutical Business Overview
Table 115. Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 116. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 117. Hoffmann-La Roche/ Chugai Pharmaceutical Recent Development
Table 118. MedImmune LLC Company Details
Table 119. MedImmune LLC Business Overview
Table 120. MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 121. MedImmune LLC Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 122. MedImmune LLC Recent Development
Table 123. RemeGen, Ltd. Company Details
Table 124. RemeGen, Ltd. Business Overview
Table 125. RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product
Table 126. RemeGen, Ltd. Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021) & (US$ Million)
Table 127. RemeGen, Ltd. Recent Development
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type: 2020 VS 2027
Figure 2. Eculizumab Features
Figure 3. Methylprednisolone Features
Figure 4. Azathioprine Features
Figure 5. Mycophenolate Mofetil Features
Figure 6. Rituximab Features
Figure 7. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application: 2020 VS 2027
Figure 8. Hospitals Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Devic’s Syndrome (Neuromyelitis Optica) Treatment Report Years Considered
Figure 12. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Regions (2022-2027)
Figure 16. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Players in 2020
Figure 17. Global Top Devic’s Syndrome (Neuromyelitis Optica) Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Devic’s Syndrome (Neuromyelitis Optica) Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue in 2020
Figure 19. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2016-2027)
Figure 23. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2016-2027)
Figure 24. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2016-2027)
Figure 25. United States Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2016-2027)
Figure 29. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2016-2027)
Figure 30. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2016-2027)
Figure 31. Germany Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Region (2016-2027)
Figure 41. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Alexion Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 61. Teva Pharmaceuticals Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 62. Fresenius Kabi AG Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 63. Pharmacia & Upjohn (a subsidary of Pfizer) Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 64. Lupin Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 65. Sagent Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 66. Zydus Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 67. Sandoz Inc. (Novartis) Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 68. Alkem Laboratories Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 69. Mylan Pharmaceuticals, Inc. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 70. Hoffmann-La Roche/ Chugai Pharmaceutical Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 71. MedImmune LLC Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 72. RemeGen, Ltd. Revenue Growth Rate in Devic’s Syndrome (Neuromyelitis Optica) Treatment Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
世界の視神経治療市場規模・現状・予測（2021年-2027年） Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and somet…- 世界の視神経スペクトラム障害（NMOSD）市場規模・現状・予測（2021年-2027年） Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of…
- 世界の肝腎症候群治療市場規模・現状・予測（2021年-2027年） Hepatorenal syndrome (often abbreviated HRS) is a life-threatening medical condition that consists of rapid deterioration in kidney function in individuals with cirrhosis or fulminant liver failure. HRS is usually fatal unless a liver transplant is performed, although various treatments, such as dia…
- 世界のグッドパスチャー症候群治療市場規模・現状・予測（2021年-2027年） Goodpasture syndrome may be caused by viral infection and / or inhalation of certain chemical substances causing primary lung damage. Market Analysis and Insights: Global Goodpasture Syndrome Treatment Market The global Goodpasture Syndrome Treatment market size is projected to reach US$ XX million …
- 世界のダンピング症候群治療市場規模・現状・予測（2021年-2027年） Dumping syndrome is a condition which develops after the surgery done to lose weight by removing all or part of the stomach. It is also called rapid gastric emptying and dumping syndrome, occurs when food especially sugar moves from the stomach into the small bowel too quickly. In some cases dumping…